IMUGENE LIMITED — Director's Dealing 2021

Oct 21, 2021

Appendix 3Y Change of Director’s Interest Notice

Rule 3.19A.2

Appendix 3Y

Change of Director’s Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.

Introduced 30/9/2001. Amended 01/01/11

	Imugene Limited (ASX: IMU)
Name of Entity:
	009 179 551
ACN:

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director:	Paul Hopper
Date of Last Notice:	13 September 2021

Part 1 - Change of director’s relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

Direct or Indirect Interest		Direct and Indirect	Direct and Indirect	Direct and Indirect
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.		Director related entity
Date of change		22 October 2021
No. of securities held prior to change			Shares Options 2,358,900 - 288,837,535 - 291,196,435 -
			Shares	Options
		Direct	2,358,900	-
		Indirect	288,837,535	-
		**Total **	291,196,435	-
Class		Fully paid	ordinary shares
Number acquired			Shares Options 1,248,600 - 99,686,613 - 100,935,213 -
			Shares	Options
		Direct	1,248,600	-
		Indirect	99,686,613	-
		**Total **	100,935,213	-
Number disposed			Shares Options - - - - - -
			Shares	Options
		Direct	-	-
		Indirect	-	-
		**Total **	-	-

• See chapter 19 for defined terms.

Appendix 3Y Page 1

01/01/2011

Appendix 3Y Change of Director’s Interest Notice

Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation		Issue price of $0.0155 per share as per resolution 2 approved by shareholders at the Extraordinary General Meeting held on 18 November 2019.	Issue price of $0.0155 per share as per resolution 2 approved by shareholders at the Extraordinary General Meeting held on 18 November 2019.	Issue price of $0.0155 per share as per resolution 2 approved by shareholders at the Extraordinary General Meeting held on 18 November 2019.
No. of securities held after change			Shares Options 3,607,500 - 388,524,148 - 392,131,648 -
			Shares	Options
		Direct	3,607,500	-
		Indirect	388,524,148	-
		**Total **	392,131,648	-
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy- back		As per resolution 2 approved by shareholders at the Extraordinary General Meeting held on 18 November 2019.

Part 2 – Change of director’s interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

• See chapter 19 for defined terms.

Appendix 3Y Page 2

01/01/2011

Appendix 3Y Change of Director’s Interest Notice

Part 3 – Closed period

Were the interests in the securities or N/A contracts detailed above traded during a +closed period where prior written clearance was required? If so, was prior written clearance N/A provided to allow the trade to proceed during this period? If prior written clearance was N/A provided, on what date was this provided?

==> picture [39 x 24] intentionally omitted <==

The CFO Solution

• See chapter 19 for defined terms.

Appendix 3Y Page 3

01/01/2011